Sweden · Delayed Price · Currency is SEK Alleima AB Earnings Call Transcripts
Fiscal Year 2026
-
Market uncertainty and Middle East instability led to lower order intake and revenues, but strong performance in medical, industrial heating, and Kanthal segments helped offset declines. Efficiency measures and a solid balance sheet support ongoing investments and resilience.
Fiscal Year 2025
-
2025 saw flat organic revenue amid geopolitical and market headwinds, with strong performance in medical, nuclear, and oil & gas offset by weakness in industrial and chem/petrochem. Efficiency measures and capacity expansions are underway, and a strong balance sheet supports continued strategy execution.
-
Profitable growth is driven by targeted investments in high-return segments like medical, nuclear, and industrial heating, supported by strong financials and a resilient, diversified portfolio. Sustained R&D, operational excellence, and a focus on sustainability underpin future value creation.
-
Challenging market conditions persist, with flat revenues and a decline in adjusted EBIT margin due to weak demand in Europe and the Americas, FX headwinds, and a prolonged maintenance shutdown. Cost-saving and restructuring measures are underway, with strong backlogs in key segments and a robust financial position.
-
Organic revenues declined 4% year-over-year amid weak demand in Europe and North America, with adjusted EBIT margin at 9.5% and strong performance in oil & gas, nuclear, and medical segments. Q3 is expected to be seasonally weaker due to extended maintenance and continued FX headwinds.
-
Solid Q1 performance with 8% organic revenue growth and 10.5% adjusted EBIT margin, supported by strong backlog and diversified segment contributions. Guidance maintained for full-year CapEx and tax, with cautious outlook amid global uncertainty.
Fiscal Year 2024
-
Organic revenue grew 1% for the year and 3% in Q4, with strong performance in oil and gas, nuclear, and medical segments, while industrial and Europe lagged. Adjusted EBIT margin was 11.5% in Q4, and the board proposed a 15% higher dividend. CapEx guidance for 2025 is SEK 1.2 billion.
-
Organic order intake declined 8% year-over-year, mainly due to oil and gas and industrial heating, while revenues grew 3% organically and adjusted EBIT margin reached 7% despite currency headwinds. Strategic investments in nuclear and medical capacity, strong cash flow, and a robust financial position support continued growth amid mixed market conditions.
-
Revenues were flat at SEK 5.4 billion with strong cash flow and resilient margins despite a 4% decline in order intake due to timing and high comparables. Market sentiment is improving, especially in industrial and consumer segments, while the company maintains a strong financial position and solid backlog.